Abstract
On current chemotherapeutic regimens, children with Philadelphia positive acute lymphoblastic leukaemia show a heterogeneous response to treatment. A few respond quickly to treatment and achieve long-term remission. Some fail to achieve remission after induction and the majority respond slowly to treatment. Relapse on treatment is common and remission is sustained in a proportion of cases only after allogeneic stem cell transplantation (allo-SCT). The use of imatinib along with conventional cytoreductive therapy, prior to allo-SCT appears to be the most promising strategy. The future lies in the molecular evaluation of response to treatment and combination targeted chemotherapy. © 2005 Blackwell Publishing Ltd.
| Original language | English |
|---|---|
| Pages (from-to) | 489-500 |
| Number of pages | 11 |
| Journal | British Journal of Haematology |
| Volume | 130 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Aug 2005 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Childhood
- Philadelphia positive acute lymphoblastic leukaemia
Fingerprint
Dive into the research topics of 'Philadelphia positive acute lymphoblastic leukaemia of childhood'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver